
Product Manual


QuickTiter™ AAV Quantitation Kit

Catalog Number

VPK-145

20 assays

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Introduction

Viral gene delivery systems include vectors developed from retrovirus (RV), adenovirus (AdV), adeno-associated virus (AAV), lentivirus (LV), and herpes simplex virus (HSV). AAV belongs to the family of Parvoviridae, a group of viruses among the smallest of single-stranded and non-enveloped DNA viruses. There are eight different AAV serotypes reported to date.

Recombinant AAV-2 is the most common serotype used in gene delivery, and it can be produced at high titers with a helper virus or Cell Biolabs' AAV Helper-Free System. AAV-2 can infect both dividing and non-dividing cells and can be maintained in the human host cell, creating the potential for long-term gene transfer. Because AAV-2 is a naturally defective virus, requiring provision of several factors in *trans* configuration for productive infection, it is considered the safest viral vector to use. Recently a new vector, AAV-DJ, was developed using DNA family shuffling to create a hybrid capsid from 8 different AAV serotypes, resulting in a vector with significantly higher *in vitro* infection rates across a variety of cells and tissues.


Recombinant AAV-2 and AAV-DJ vectors can be purified by CsCl gradient ultracentrifugation, iodixanol discontinuous gradient ultracentrifugation, or Cell Biolabs' ViraBind™ AAV Purification Kit.

A particular challenge in the delivery of a gene by a viral vector is the accurate measurement of virus titer. Traditionally, AAV particles are measured by DNA dot blot or similar approaches. These methods are time-consuming and suffer from a high degree of inter-assay variability. For highly purified virus samples, an optical absorbance at 260 nm has been used to estimate the total number of virus particles. However this method cannot be used in an unpurified viral supernatant, because other components it contains can contribute to the optical absorbance of 260 nm. An ELISA method has been developed by using antibody that only reacts with AAV intact particles; however, this method measures all AAV particles including the ones lacking genomic DNA.

Cell Biolabs' proprietary QuickTiter™ AAV Quantitation Kit does not involve cell infection; instead it specifically measures the viral nucleic acid content of purified viruses or unpurified viral supernatant sample (See Assay Principle). The kit is especially useful for determining the supernatant titer before the purification step. The kit has a detection sensitivity limit of 1×10^9 GC/mL (genome copy/mL) for unpurified AAV-2 or AAV-DJ supernatants, or 5×10^{10} GC/mL for purified AAV sample from any serotype, which is sufficient for mid or high-titer AAV samples. The entire procedure takes about 4 hours for unpurified supernatant or about 30 minutes for purified AAV. Each kit provides sufficient quantities to perform up to 20 tests for unpurified AAV-2 or AAV-DJ samples generated from the AAV Helper-Free System.

QuickTiter™ AAV Quantitation Kit provides an efficient system for rapid quantitation of AAV titer for both viral supernatant and purified virus.

Assay Principle



Related Products

1. AAV-100: 293AAV Cell Line
2. AAV-200: ViraDuctin™ AAV Transduction Kit
3. VPK-140: ViraBind™ AAV Purification Kit
4. VPK-109: QuickTiter™ Adenovirus Titer Immunoassay Kit
5. VPK-5211: QuickTiter™ AAV Titer ELISA Kit

Kit Components (shipped at room temperature)

1. ViraBind™ AAV Reagent A (Part No. 314001): One 0.3 mL tube.
2. ViraBind™ AAV Reagent B (Part No. 314002): One 1.5 mL tube.
3. QuickTiter™ AAV Capture Matrix (Part No. 314501): One 1 mL tube.
4. QuickTiter™ AAV Wash Solution (5X) (Part No. 314502): One 10 mL bottle.
5. QuickTiter™ Solution C (10X) (Part No. 314503): One 5 mL bottle.
6. CyQuant® GR Dye (400X) (Part No. 105101): One 50 µL tube.
7. QuickTiter™ AAV DNA Standard (Part No. 314504): One 500 µL tube containing 100 µg/mL AAV DNA Standard.

Materials Not Supplied

1. AAV Helper-Free System
2. HEK 293 cells and cell culture growth medium
3. Cell culture centrifuge
4. 1X TE (10 mM Tris, pH 7.5, 1 mM EDTA)
5. Fluorescence Plate Reader

Storage

Store ViraBind™ AAV Reagent B at room temperature and all other kit components at 4°C.

Safety Considerations

Remember that you will be working with samples containing infectious virus. Follow the recommended NIH guidelines for all materials containing BSL-2 organisms.

Preparation of Reagents

- 1X QuickTiter™ AAV Wash Solution: Prepare a 1X QuickTiter™ AAV Wash Solution by diluting the provided 5X stock 1:5 in deionized water. Store the diluted solution at room temperature.

- 1X QuickTiter™ Solution C: Prepare a 1X QuickTiter™ Solution C by diluting the provided 10X stock to 1X with 1X TE. Store the diluted solution at room temperature.

Note: Only dilute the amount of QuickTiter™ Solution C needed to prepare the Standard Curve and unpurified samples. If purified AAV samples will be tested, the 10X QuickTiter™ Solution C will be used undiluted.

- 1X CyQuant® GR Dye: Estimate the amount of 1X CyQuant® GR Dye needed based on the number of assays including AAV DNA standard samples. Immediately before use, prepare a 1X CyQuant® GR Dye by diluting the provided 400X stock 1:400 in 1X TE. For best results, the diluted solution should be used within 2 hrs of its preparation.

Preparation of Standard Curve

1. Create AAV DNA standards from 10 µg/mL, 5 µg/mL, 2.5 µg/mL, 1.25 µg/mL,... 0 µg/mL (using 1:2 serial dilutions).

Standard Tubes	100 µg/mL AAV DNA Standard (µL)	1X QuickTiter™ Solution C (µL)	AAV DNA Standard (µg/mL)
1	10	90	10
2	50 of Tube #1	50	5
3	50 of Tube #2	50	2.5
4	50 of Tube #3	50	1.25
5	50 of Tube #4	50	0.625
6	50 of Tube #5	50	0.313
7	50 of Tube #6	50	0.156
8	50 of Tube #7	50	0.078
9	50 of Tube #8	50	0.039
10	50 of Tube #9	50	0.020
11	50 of Tube #10	50	0.010
12	0	50	0

2. Transfer 10 µL of each dilution including blank to a microtiter plate suitable for reading on a fluorometer. Add 90 µL of 1X CyQuant® GR Dye to each of the wells containing the 10 µL sample. Read the plate with a fluorescence plate reader using a 480/520 nm filter set.

Preparation of rAAV Samples

The following procedure is suggested for one 15 cm dish or two 10 cm dishes and may be optimized to suit individual needs. For best results please refer to your user manual for Cell Biolabs' AAV Helper-Free System or other system you are using. In general, each cell produces about 20,000 to 100,000 viral particles under optimized conditions.

1. Use HEK 293 cells that have been passaged 2-3 times prior to transfection. Culture these cells until the monolayer is 70-80% confluent.
2. Cotransfect cells with the pAAV-RC, pHelper and your expression construct according to manufacturer's manual.
3. After 48-72 hrs, harvest the transfected cells plus culture medium in a conical tube and centrifuge for 5 min at 3000 rpm to pellet the transfected cells. Resuspend the cell pellet in 2.5 mL of serum-free DMEM.
4. Subject the cell suspension to four rounds of freeze/thaw cycles by alternating the tubes between the dry ice-ethanol bath and the 37°C water bath.
5. Collect the AAV supernatant by centrifugation at 10,000 x g for 10 minutes. Discard the pellet.
6. The viral supernatant can be stored at -80°C or immediately titered or purified.

Assay Protocol

I. Unpurified AAV-2 or AAV-DJ Samples

Note: The following procedure is written for quantitation of 1.0 mL of unpurified AAV-2 or AAV-DJ supernatant. For AAV samples that are less than 1.0 mL, add serum-free DMEM to the final volume of 1.0 mL.

1. Add 10 µL of ViraBind™ AAV Reagent A to 1.0 mL of viral supernatant, mixing well.
2. Incubate for 30 minutes at 37°C.
3. Incubate ViraBind™ AAV Reagent B for 30-60 minutes at 37°C to ensure Reagent B is dissolved. Add 50 µL of ViraBind™ AAV Reagent B to the viral supernatant pre-treated with ViraBind™ AAV Reagent A, mixing well.
4. Incubate for 30 minutes at 37°C.
5. Resuspend the QuickTiter™ AAV Capture Matrix by inverting and shaking. Add 50 µL of matrix to the virus supernatant.
6. Mix the supernatant/matrix suspension at room temperature for 30 minutes on a shaker.
7. Pellet the AAV Capture Matrix by centrifugation for 10 minutes at 1,000 rpm.
8. Carefully remove the supernatant and wash the AAV Capture Matrix with 1.0 mL of 1X QuickTiter™ AAV Wash Solution. Pellet the AAV Capture Matrix by centrifugation for 5 minutes at 1,000 rpm and carefully remove the supernatant.
9. Repeat the wash step once and aspirate the final wash. To remove the last bit of liquid, centrifuge the tube again at 2000 rpm for 30 seconds, and remove remaining supernatant with a small bore pipette tip to avoid disturbing the beads.
10. Add 20 µL of 1X QuickTiter™ Solution C and mix with the beads by vortexing for 30 seconds. Incubate 1 hr at 75°C. Spin down the beads at 12,000 rpm for 30 seconds.
11. Transfer 10 µL supernatant to a microtiter plate suitable for fluorometer. Add 90 µL of freshly prepared 1X CyQuant® GR Dye to well(s) containing the 10 µL supernatant. Read the plate with a fluorescence plate reader using a 480/520 nm filter set.
12. Calculate AAV titer based on the standard curve.

II. Purified AAV Sample

1. Mix 13.5 μL of purified AAV sample and 1.5 μL of 10X QuickTiter™ Solution C in a tube and incubate 1 hr at 75°C. Spin briefly to collect condensation. Incubate 20 minutes at room temperature.
2. Prepare a non-heated control sample by mixing 13.5 μL of the same purified AAV sample and 1.5 μL of 10X QuickTiter™ Solution C in a tube.
3. Transfer 10 μL of the mixtures including the non-heated control sample to a microtiter plate suitable for reading in a fluorometer. Add 90 μL of freshly prepared 1X CyQuant® GR Dye to each well containing the 10 μL supernatant. Read the plate with a fluorescence plate reader using a 480/520 nm filter set.
4. Calculate AAV titer based on the standard curve.

Example of Results

The following figures demonstrate typical quantitation results. One should use the data below for reference only. This data should not be used to interpret actual results.




Figure 1: AAV-2 DNA Standard Curve. The QuickTiter™ AAV-2 DNA Standard was diluted as described in the Assay Protocol. Fluorescence measurement was performed with a 485/538 nm filter set and 530 nm cutoff.

Calculation of AAV-2 Titer (Genome Copy (GC)/mL)

1. Determine AAV-2 DNA amount:

- 1) Calculate Net RFU (Relative Fluorescence Unit):
Net RFU = RFU (viral sample) – RFU (negative control corresponding to viral sample)
- 2) Use the standard curve to determine the viral DNA amount of each unknown sample.

2. Calculate Viral Titer:

The average genome size of an AAV-2 is 5000 base, therefore:

$$1 \text{ ng AAV-2 DNA} = (1 \times 10^{-9}) \text{ g} / (5000 \text{ base} \times 330 \text{ g/base}) \times 6 \times 10^{23} = 3.6 \times 10^8 \text{ GC}$$

(a) For unpurified AAV-2 sample:

Net RFU = RFU (viral sample) – RFU (0 ng/mL standard)

$$\text{Titer (GC/mL)} = \frac{\text{Dilution Factor} \times \text{AAV-2 DNA (ng)} \times (3.6 \times 10^8 \text{ GC/ng}) \times (20 \mu\text{L}/10 \mu\text{L})}{1.0 \text{ mL}}$$

(b) For purified AAV-2 sample:

Net RFU = RFU (viral sample) – RFU (non-heated control sample)

$$\text{Titer (GC/mL)} = \frac{\text{Dilution Factor} \times \text{AAV-2 DNA (ng)} \times (3.6 \times 10^8 \text{ GC/ng}) \times (15 \mu\text{L}/13.5 \mu\text{L})}{0.010 \text{ mL}}$$

Calculation Example

Purified AAV-2-GFP (ViraBind™ AAV Purification Kit): undiluted purified AAV-2-GFP was used as described in Assay Protocol

Net RFU = 54.6 – 3.3 = 51.3 or 28 ng of viral DNA

$$\text{Titer (GC/mL)} = \frac{\text{Dilution Factor} \times \text{AAV-2 DNA (ng)} \times (3.6 \times 10^8 \text{ GC/ng}) \times (15 \mu\text{L}/13.5 \mu\text{L})}{0.010 \text{ mL}}$$

$$\text{Titer (GC/mL)} = \frac{1 \times 28 \text{ (ng)} \times (3.6 \times 10^8 \text{ GC/ng}) \times (15 \mu\text{L}/13.5 \mu\text{L})}{0.010 \text{ mL}} = 1.12 \times 10^{12} \text{ GC/mL}$$

References

1. Rabinowitz, J, and Samulski, R. J. (1998) *Curr. Opin. Biotechnol.*, **9**, 470-475.
2. Summerford, C., and Samulski, R. J. (1999) *Nat. Med.*, **5**, 587-588.
3. Clark, K., Liu, X., McGrath, J., and Johnson, P. (1999) *Hum. Gene Ther.*, **10**, 1031-1039.

Recent Product Citations

1. Tian, F. et al. (2026). STUB1-induced polyubiquitination of SIK3 in alveolar type 2 epithelial cells alleviates severity and outcomes of acute lung injury. *Cell Death Dis.* doi: 10.1038/s41419-026-08822-x.
2. Rees-Spear, C. et al. (2026). High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies. *NPJ Vaccines.* doi: 10.1038/s41541-026-01468-y.
3. Tang, X. et al. (2024). Adeno-Associated Virus (AAV)-Delivered Exosomal TAT and BiTE Molecule CD4-αCD3 Facilitate the Elimination of CD4 T Cells Harboring Latent HIV-1. *Microorganisms.* **12**(8):1707. doi: 10.3390/microorganisms12081707.
4. Bahal, S. et al. (2024). Hematopoietic stem cell gene editing rescues B-cell development in X-linked agammaglobulinemia. *J Allergy Clin Immunol.* **154**(1):195-208.e8. doi: 10.1016/j.jaci.2024.03.003.
5. He, X. et al. (2023). NeuroD1 Regulated Endothelial Gene Expression to Modulate Transduction of AAV-PHP.eB and Recovery Progress after Ischemic Stroke. *Aging Dis.* doi: 10.14336/AD.2023.1213.
6. Ou, D.L. et al. (2024). Nano-modified viruses prime the tumor microenvironment and promote the photodynamic virotherapy in liver cancer. *J Biomed Sci.* **31**(1):1. doi: 10.1186/s12929-023-00989-1.

7. Tsuyama, T. et al. (2023). Hypoxia causes pancreatic β -cell dysfunction and impairs insulin secretion by activating the transcriptional repressor BHLHE40. *EMBO Rep*. doi: 10.15252/embr.202256227.
8. Iwasaki, M. et al. (2023). An analgesic pathway from parvocellular oxytocin neurons to the periaqueductal gray in rats. *Nat Commun*. **14**(1):1066. doi: 10.1038/s41467-023-36641-7.
9. Fox, T.A. et al. (2022). Therapeutic gene editing of T cells to correct CTLA-4 insufficiency. *Sci Transl Med*. **14**(668):eabn5811. doi: 10.1126/scitranslmed.abn5811.
10. Yang, J. et al. (2022). Functionally distinct NPAS4-expressing somatostatin interneuron ensembles critical for motor skill learning. *Neuron*. doi: 10.1016/j.neuron.2022.08.018.
11. Yoshizawa, T. et al. (2022). SIRT7 suppresses energy expenditure and thermogenesis by regulating brown adipose tissue functions in mice. *Nat Commun*. **13**(1):7439. doi: 10.1038/s41467-022-35219-z.
12. Furuuchi, R. et al. (2022). Endothelial SIRT-1 has a critical role for the maintenance of capillarization in brown adipose tissue. *iScience*. doi: 10.1016/j.isci.2022.105424.
13. Furuuchi, R. et al. (2022). Endothelial SIRT-1 has a critical role for the maintenance of capillarization in brown adipose tissue. *iScience*. doi: 10.1016/j.isci.2022.105424.
14. Kennedy, A. et al. (2022). Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation. *Nat Immunol*. **23**(9):1365-1378. doi: 10.1038/s41590-022-01289-w.
15. Hsieh, C.C. et al. (2022). Macrophage Distribution Affected by Virus-Encoded Granulocyte Macrophage Colony Stimulating Factor Combined with Lactate Oxidase. *ACS Omega*. doi: 10.1021/acsomega.2c03213.
16. Hayashi, Y. et al. (2022). Coagulation factors promote brown adipose tissue dysfunction and abnormal systemic metabolism in obesity. *iScience*. doi: 10.1016/j.isci.2022.104547.
17. Yoshida, Y. et al. (2022). Differing impact of phosphoglycerate mutase 1-deficiency on brown and white adipose tissue. *iScience*. doi: 10.1016/j.isci.2022.104268.
18. Xu, M. et al. (2022). The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rbdf2 in mouse hepatocytes. *Nat Commun*. **13**(1):1052. doi: 10.1038/s41467-022-28641-w.
19. Kashihara, T. et al. (2022). YAP mediates compensatory cardiac hypertrophy through aerobic glycolysis in response to pressure overload. *J Clin Invest*. doi: 10.1172/JCI150595.
20. Paiva, L. et al. (2021). Identification of peripheral oxytocin-expressing cells using systemically applied cell-type specific adeno-associated viral vector. *J Neuroendocrinol*. doi: 10.1111/jne.12970.
21. Wahis, J. et al. (2021). Astrocytes mediate the effect of oxytocin in the central amygdala on neuronal activity and affective states in rodents. *Nat Neurosci*. doi: 10.1038/s41593-021-00800-0.
22. Francisco, J. et al. (2021). AAV-mediated YAP expression in cardiac fibroblasts promotes inflammation and increases fibrosis. *Sci Rep*. **11**(1):10553. doi: 10.1038/s41598-021-89989-5.
23. Kwon, O.C. et al. (2021). SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models. *EMBO Mol Med*. doi: 10.15252/emmm.202013076.
24. Lebeau, P.F. et al. (2020). The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. *J Clin Invest*. doi: 10.1172/JCI128650.
25. Kawaguchi, Y. et al. (2020). Endoplasmic reticulum chaperone BiP/GRP78 knockdown leads to autophagy and cell death of arginine vasopressin neurons in mice. *Sci Rep*. **10**(1):19730. doi: 10.1038/s41598-020-76839-z.
26. Rai, R. et al. (2020). Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome. *Nat Commun*. **11**(1):4034. doi: 10.1038/s41467-020-17626-2.

26. Zeng, J. et al (2020). The Zika Virus Capsid Disrupts Corticogenesis by Suppressing Dicer Activity and miRNA Biogenesis. *Cell Stem Cell*. S1934-5909(20)30350-7. doi: 10.1016/j.stem.2020.07.012.
27. Tang, Y. et al. (2020). Social touch promotes interfemale communication via activation of parvocellular oxytocin neurons. *Nat Neurosci*. doi: 10.1038/s41593-020-0674-y.
28. Zhu, J. et al. (2020). Preparation of a Bacteriophage T4-based Prokaryotic-eukaryotic Hybrid Viral Vector for Delivery of Large Cargos of Genes and Proteins into Human Cells. *Bio-protocol*. **10**(07): e3573. doi: 10.21769/BioProtoc.3573.
29. Wu, Z. et al. (2020). Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease. *Nat Commun*. **11**(1):1105. doi: 10.1038/s41467-020-14855-3.
30. Zhang, H. et al. (2020). Vitamin D receptor targets hepatocyte nuclear factor 4 α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease. *J Biol Chem*. pii: jbc.RA119.011487. doi: 10.1074/jbc.RA119.011487.

License Information

This product is provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@lifetech.com.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS' sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

Contact Information

Cell Biolabs, Inc.
5628 Copley Drive
San Diego, CA 92111
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2008-2026: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.